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Gangwal et al. (2011) addressed an impor-
tant topic for nanotoxicology about assess-
ing the toxicity of inhaled nano  materials by 
recom  mending relevant concentrations for 
in vitro toxicity testing. Their efforts to select 
in vitro concentrations based on reported 
occupational exposure levels of inhaled 
nano  materials are, indeed, laudable. Their 
under  lying conceptual approach is logical, 
involving a widely used and well-accepted 
particle dosimetry model [multiple-path 
particle dosimetry (MPPD)] to estimate 
deposited and retained mass doses in the 
pulmonary alveolar region of nano  material-
exposed workers. They then expressed these 
doses as per-unit alveolar surface area in 
order to select for in vitro testing the same 
alveolar epithelial cell surface area doses. 
However, while this concept makes good 
sense when applying it to short-term (daily) 
deposited doses, it makes less sense and 
can be highly misleading when the same 
approach is used for doses that have accumu-
lated in the alveo  lar region after long-term 
chronic inhalation exposures of humans. 
Thus, it is unfortunate that the authors made 
it a main point to estimate (although crudely 
and with some questionable assumptions) 
the dose of inhaled nano  materials that is 
retained or accumulated on the pulmonary 
alveolar surface over a full working lifetime 
of 45 years of exposure to 1 mg/m3 airborne 
concentration. Gangwal et al. then converted 
this 45-year accumulated surface area dose 
to an equivalent in vitro concentration (per 
square centi  meter) as a selection criterion 
for in vitro dosing. Under “Concentrations 
recommended for in vitro testing,” they con-
cluded that the long-term retained human 
alveo  lar surface area dose equates to in vitro 
concentrations of 50–68 µg/mL and that 
These amounts for a full working lifetime lie 
within the range of the highest in vitro assay con-
centrations tested in the literature for Ag [silver 
nano  particles] and TiO2 [titanium dioxide nano-
particles] on human, rat, and mouse cell lines. 
(Gangwal et al. 2011)
These are extraordinarily high concentra-
tions, and unfortunately this article may be 
viewed as a justification for using such high 
in vitro dosing uncritically. Gangwal et al. 
(2011) did not discuss anywhere in the arti-
cle the reasoning behind equating lifetime 
accumulated doses with doses that are given 
all at once as a bolus in a short-term in vitro 
system. The difference in dose rate alone—
not considering anything else—spans many 
orders of magnitude. At best, these extrapo-
lated high in vitro concentrations may be 
labeled as the high-end limit of an in vitro 
study using a wide range of doses.
To their credit, Gangwal et al. (2011) 
estimated lung surface area doses achieved 
for a 24-hr exposure to an inhaled concen-
tration of 1 mg/m3 and—as one would 
expect—extrapolated this to much lower 
concentrations of 0.17–0.57 µg/mL for 
equivalent in vitro dosing with TiO2 and 
Ag nano  particles. If they had used a more 
realistic higher value for the human alveolar 
surface area—as they did for the full working 
lifetime exposure—the extrapolated equiva-
lent short-term in vitro concentrations would 
have been even lower by about one order of 
magnitude. Unfortunately, the authors did 
not emphasize the tremendous differences 
between actual high doses used in most pub-
lished in vitro studies of nano  particles and 
the more realistic much lower in vitro doses. 
For in vitro testing, use of a wide range of 
doses, starting at—or even better—below 
the 24-hr inhalation equivalent and increas-
ing to a maximum of the lifetime exposure 
equivalent, could be a practical approach. 
With respect to carbon nano  tubes 
(CNTs), Gangwal et al. (2011) reported 
results only for the full working lifetime 
exposure scenario and the resulting extrapo-
lated equivalent in vitro concentrations. 
According to the authors, these extrapolated 
high equivalent in vitro concentrations are at 
the low end of concentrations that have been 
reported for CNTs in the in vitro literature. 
Implications for selection of realis  tic in vitro 
exposures to CNTs were not discussed, nor 
was the more relevant 24-hr exposure sce-
nario for CNTs modeled to derive an equiv-
alent short-term in vitro dose. This would 
have provided a suggested range of in vitro 
dosing for CNTs as pointed out above for 
Ag and TiO2 nano  particles, provided the 
dosimetry model (MPPD) is applicable for 
CNTs. Unfortunately, the validity of the 
MPPD model for fiber-shaped structures of 
nano    sized dimensions was neither explained 
in sufficient detail by Gangwal et al., nor has 
it been confirmed and published, specifically 
for nano  fibers and nano  tubes. Moreover, 
a thorough literature search reveals that 
CNT aerosols at workplaces are not present 
as individual straight nano  fibers, but occur 
mostly as small and large tangles of differ-
ent shapes of hollow tubes with unknown 
effective density (density is not that of solid 
carbon) (Han et al. 2008; Methner et al. 
2010; Tsai et al. 2009). There is currently 
no deposition model that could be applied 
for such nano  structures without additional 
research to obtain necessary input data.
A careful selection of in vitro doses for 
nano  particle toxicity testing is very important. 
Thus, authors, reviewers, and journal editors 
should be critical when submitting, reviewing, 
and accepting papers for publication.
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We appreciate the letter from Oberdörster 
commenting on the importance of careful 
selection of in vitro doses for nano  material 
(NM) toxicity testing and his assessment of 
our article (Gangwal et al. 2011). Because the 
objective of our study was to use limited data 
on potential human occupational exposure to 
NMs to identify bounding limits for toxic-
ity testing, we believe our conclusions and 
Oberdörster’s views to be generally aligned. 
Our article described how to apply sparse 
NM exposure information from manufactur-
ing and R&D (research and develop  ment) 
settings and relevant particle dosimetry model 
inputs, based on a report of the International 
Commission on Radiological Protection 
(1994), to estimate NM mass retained in the 
alveolar region of the human lung. Modeled 
alveolar lung surface concentrations (micro-
grams per square centimeter) were then used 
to estimate bounding in vitro NM solution 
concentrations (micrograms per milli  liter) 
representative of short-term (24-hr) and long-
term (full occupational lifetime of 45 years) 
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